MTOR and breast carcinoma: The first generation of mTOR inhibitors only targets mTORC1, such as everolimus, which can bind to the intracellular receptor FK506-binding protein 12 to inhibit the activity of mTOR kinase and the production of mTORC1 complex, thereby it can inhibit angiogenesis and achieve the purpose of treating breast cancer (41).